Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

102.03 +1.96 (+1.96%)
Official Closing Price Updated: 7:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,963,596
Open 100.61
Bid (Size) 102.03 (6)
Ask (Size) 102.50 (1)
Prev. Close 100.07
Today's Range 100.08 - 102.40
52wk Range 89.67 - 121.64
Shares Outstanding 1,750,942,289
Dividend Yield 2.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Laboratories is launching Lingo, an over-the-counter glucose monitoring device aimed at non-diabetic consumers, utilizing TV and guerilla marketing. CEO Robert Ford expects Lingo to become a... 
Via Benzinga

Performance

YTD
-7.12%
-7.12%
1 Month
-4.26%
-4.26%
3 Month
-4.71%
-4.71%
6 Month
-10.65%
-10.65%
1 Year
-10.73%
-10.73%

More News

Read More
Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims
Via Benzinga
Topics Stocks
Exposures US Equities
7 Safe Stocks to Buy for Volatility Insurance
Via InvestorPlace
Abbott Laboratories Earnings Top Views, Full-Year Guidance Raised
Via Investor's Business Daily
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Are Abbott Laboratories Shares Trading Lower?
Via Benzinga
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
ABT Stock Earnings: Abbott Laboratories Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Via Benzinga
Exposures Product Safety
Why This Leading Health Stock is a Buy No Matter the Market Move
Via MarketBeat
Exposures COVID-19
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Via Benzinga
Topics Economy
Exposures Interest Rates
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Nasdaq Sees Worst Session Since 2022 As Chip Stocks Tumble After Trump's Taiwan Remarks and Biden's Potential Restrictions
Via Benzinga
Topics Government
Exposures Political
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Dow Closes At New High As Q2 Earnings Season Heats Up
Via Talk Markets
Topics Stocks
Exposures US Equities
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Via Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
From Financial Buzz Media
Via GlobeNewswire
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The 3 Best Healthcare Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.